MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 01-08-2026
Tilray Total Assets 2011-2026 | TLRY
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Tilray
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.31 B | 5.45 B | 6.03 B | 2.5 B | 2.44 B | 1.31 B | 316 M | 36.3 M | 14.3 M | 184 K | 298 K | 342 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.03 B | 184 K | 1.87 B |
Quarterly Total Assets Tilray
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.1 B | 2.08 B | 2.07 B | - | 3.4 B | 4.26 B | 4.22 B | 4.21 B | 4.22 B | 4.4 B | 4.31 B | 4.38 B | 5.47 B | 5.59 B | 5.45 B | 5.45 B | 5.76 B | 5.99 B | 6.03 B | 6.03 B | 946 M | 887 M | 856 M | 916 M | 896 M | 896 M | 896 M | 896 M | 657 M | 657 M | 657 M | 657 M | 53.9 M | 53.9 M | 53.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.03 B | 53.9 M | 2.81 B |
Total Assets of other stocks in the Drug manufacturers industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
431 M | - | - | $ 754 M |  USA |
 |
Alimera Sciences
ALIM
|
154 M | - | - | $ 142 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
18.2 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
10.9 M | - | 0.86 % | $ 117 M | USA |
 |
Agile Therapeutics
AGRX
|
10.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
Canopy Growth Corporation
CGC
|
918 M | $ 1.1 | 2.84 % | $ 118 M |  Canada |
 |
Cronos Group
CRON
|
1.93 B | $ 2.64 | 1.35 % | $ 1.38 B | Canada |
 |
Catalent
CTLT
|
9.75 B | - | - | $ 11.5 B | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
164 M | - | - | $ 2.06 B |  France |
 |
China Pharma Holdings
CPHI
|
14.9 M | $ 0.59 | 6.08 % | $ 10.3 M |  China |
 |
DURECT Corporation
DRRX
|
45.2 M | - | - | $ 50.1 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
75.6 M | $ 3.81 | -16.81 % | $ 53.6 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
406 M | - | -39.89 % | $ 27.7 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1.46 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Endo International plc
ENDP
|
5.14 B | - | - | $ 28.9 M |  Irlanda |
 |
Evolus
EOLS
|
226 M | $ 5.68 | 37.53 % | $ 366 M | USA |
 |
HEXO Corp.
HEXO
|
681 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Evoke Pharma
EVOK
|
7.07 M | - | - | $ 36.6 M | USA |
 |
Harrow Health
HROW
|
399 M | $ 40.02 | 3.65 % | $ 1.47 B | USA |
 |
Aurora Cannabis
ACB
|
853 M | $ 3.65 | 4.89 % | $ 86.3 M | Canada |
 |
Athenex
ATNX
|
204 M | - | -23.39 % | $ 1.76 M | USA |
 |
Jupiter Wellness
JUPW
|
7.34 M | - | - | $ 33.6 M | USA |
 |
Emergent BioSolutions
EBS
|
1.82 B | $ 8.95 | 0.39 % | $ 458 M | USA |
 |
Assertio Holdings
ASRT
|
286 M | $ 12.19 | 2.48 % | $ 866 M | USA |
 |
Bausch Health Companies
BHC
|
27.4 B | $ 5.67 | -0.87 % | $ 2.07 B | Canada |
 |
Lannett Company
LCI
|
484 M | - | 1.15 % | $ 7.11 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
223 M | - | - | $ 193 M | Canada |
 |
OrganiGram Holdings
OGI
|
408 M | $ 1.4 | 2.19 % | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
498 M | $ 2.87 | 0.01 % | $ 378 M | USA |
 |
Sundial Growers
SNDL
|
1.35 B | $ 1.55 | 1.21 % | $ 3.37 M | Canada |
 |
Perrigo Company plc
PRGO
|
8.54 B | $ 11.71 | 2.81 % | $ 1.62 B | USA |
 |
ProPhase Labs
PRPH
|
87.6 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
182 M | - | - | $ 1.42 B | USA |
 |
Rockwell Medical
RMTI
|
52.2 M | $ 0.91 | 1.03 % | $ 21.2 M | USA |
 |
Pacira BioSciences
PCRX
|
1.55 B | $ 22.92 | 3.69 % | $ 1.06 B | USA |
 |
PetIQ
PETQ
|
868 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
108 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
76.6 M | - | -27.8 % | $ 2.56 M | USA |
 |
Recro Pharma
REPH
|
153 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
97.6 M | $ 4.79 | 2.57 % | $ 144 M | USA |
 |
SCYNEXIS
SCYX
|
59 M | $ 0.76 | 1.22 % | $ 36.4 M | USA |
 |
Solid Biosciences
SLDB
|
189 M | $ 6.14 | 3.02 % | $ 251 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
13.7 M | $ 2.74 | -0.36 % | $ 3.4 M | USA |
 |
Tricida
TCDA
|
169 M | - | - | $ 3.25 M | USA |
 |
TherapeuticsMD
TXMD
|
43.3 M | $ 2.25 | 1.35 % | $ 23.5 M | USA |
 |
Veru
VERU
|
60.4 M | $ 2.53 | 0.4 % | $ 341 M | USA |
 |
Viatris
VTRS
|
50 B | $ 14.74 | -1.04 % | $ 17.7 B | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
55.5 M | - | - | $ 55.5 M | USA |
 |
cbdMD
YCBD
|
10.6 M | $ 0.75 | -2.76 % | $ 3.23 M | USA |